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Abstract
The balance between immune effector cells such as T cells and natural killer cells, and immunosuppressive Treg
cells, dendritic, myeloid and monocytic sub-populations in the tumor microenvironment acts to calibrate the immune
response to malignant cells. Accumulating evidence is pointing to a role for B cells in modulating the immune
response to both solid tumors and hematologic cancer. Evidence from murine autoimmune models has defined
B regulatory cell (Breg) subsets that express cytokines such as IL-10, TGF-β, and/or express immune regulatory
ligands such as PD-L1, which can suppress T cell and/or natural killer cell responses. Multiple murine tumor models
exhibit decreased tumor growth in B cell deficient or B cell depleted mice. In several of these models, B cells inhibit
T cell mediated tumor immunity and/or facilitate conversion of T cells to CD4+CD25+FoxP3+ T regs, which act to
attenuate the innate and/or adaptive antitumor immune response.
Mechanisms of suppression include the acquisition of inhibitory ligand expression, and phosphorylation of Stat3,
and induction of IL-10 and TGF-β, resulting in a Breg phenotype. Breg suppressive activity may affect diverse cell
subtypes, including T effector cells, NK cells, myeloid derived suppressor cells (MDSC) and/or tumor associated
macrophages. B cells may also directly promote tumorigenesis through recruitment of inflammatory cells, and
upregulation of pro-angiogenic genes and pro-metastatic collagenases.
Breg infiltration has now been identified in a variety of solid tumor malignancies including but not limited to
ovarian, gastric, non-small cell lung cancer, pancreatic, esophageal, head and neck, and hepatocellular carcinomas.
Increasing evidence suggests that recruitment of B cells and acquisition of suppressive activity within the tumor bed
may be an important mechanism through which B cells may modulate innate and/or adaptive anti-tumor immunity.
B cell depletion in the clinic using anti-CD20 antibodies and/or inhibitors of BTK and/or other signaling pathways, may
be a useful strategy for augmenting the anti-tumor immune response.
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Background
A subset of B cells identified as B-regulatory cells (Bregs)
have recently emerged as major contributors to the
pathogenesis of autoimmune and neoplastic disorders.
In neoplastic disorders, Bregs are generated in response
to signals from the tumor microenvironment and in turn
promote tumor growth through interactions with T-
regulatory cells (Tregs), myeloid-derived suppressor cells
(MDSC), tumor-associated macrophages, CD4+ and
CD8+ T lymphocytes, natural killer (NK) cells, and dir-
ect interactions with tumor cells. A role for B cells in
anti-tumor immunity was first established by Brodt and
Gordon [1] and Monach et al. [2], who demonstrated
that tumor growth was diminished in B-cell depleted
mice. Qin et al. [3] and Shah et al. [4] later demonstrated
that B cells inhibit CTL-mediated tumor immunity.
More recently Olkhanud et al. [5] and Tadmor et al. [6]
showed that Bregs may facilitate the conversion of CD4
+CD25− T cells to CD4+CD25+FoxP3+ Tregs, which in
turn attenuate the innate anti-tumor cellular immune
response.
Effects of Breg cells in murine tumor models sug-
gested that similar B regulatory activity would also be
identified in human tumors. While some studies suggest
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that tumor-infiltrating B cells have a protective role
against disease progression [7–12], other studies suggest
that Bregs are upregulated in patients with solid tumor
malignancies and are associated with enhanced tumor-
aggressiveness and poorer prognosis [13–25]. In human
lymphoid malignancies, malignant B cells appear to act
as Bregs by suppressing the anti-tumor cellular immune
response through expression of suppressive ligands [26–
29]. This has led to successful targeting of B-regulatory
functions of malignant B cells in lymphomas, which have
thus far shown remarkably favorable outcomes in several
clinical trials [26–28]. These results have lent credence
to the notion that Breg activity may be modulating im-
mune responses against non-lymphoid solid tumors.
Bregs have now been identified in humans with a variety
of solid tumor malignancies including ovarian, gastric,
lung, colorectal, pancreatic, breast, esophageal, bladder,
squamous cell, and hepatocellular carcinomas [13–22,
24, 25]. These observations suggest that targeting of
Breg activity may be used to enhance immunotherapeu-
tic outcomes.
Breg subtypes in autoimmune disease and cancer
I.) Role of IL-10 in B cell regulatory function
IL-10 exerts anti-inflammatory effects in mouse and hu-
man cells via suppression of Th1 and Th17 responses, pro-
motion of CD4+CD25+FoxP3+ Treg generation, and
suppression of the release of macrophage- and monocyte-
produced inflammatory cytokines [30–33]. B cells with
regulatory function were initially described in murine
models of autoimmune diseases such as experimental
autoimmune encephalitis (EAE), collagen-induced arth-
ritis (CIA), and inflammatory bowel disease (IBD), in
which B cell deficient mice developed severe non-
remitting disease that was ameliorated with B cell adoptive
transfer [15–20, 34–39]. Fillatreau et al. [36] showed that
mice which had recovered from EAE produced IL-10 in
response to autoantigen, while mice incapable of produ-
cing IL-10 developed severe non-remitting EAE. Mice
with IL-10 deficiency restricted to B cells also developed
severe non-remitting EAE, which could be ameliorated
through the adoptive transfer of IL-10-producing B cells
from wild type (WT) mice that had recovered from EAE.
CD40-CD40L interaction was recognized as an essential
step in the generation of IL-10-producing B cells in re-
sponse to autoantigen [36]. This and similar results in
other mouse autoimmune models [32–34, 38–42] impli-
cated IL-10 as a principal effector of B cell immune-
regulatory activity. Decreased frequency and dysfunction
of IL-10+ Bregs have been described in humans with vari-
ous autoimmune disorders such as rheumatoid arthritis,
systemic lupus erythematosus (SLE), inflammatory bowel
disease, graft-versus-host disease, and vasculitides [43–
52]. Enhancement of peripheral and organ-specific Bregs
has been shown to be protective in patients with severe
acute pancreatitis [53] but also has been associated with
advanced histological fibrosis stages in patients with
chronic hepatitis B virus infection [54], suggesting that
Breg-mediated immune suppression may be beneficial in
acute inflammatory states but harmful in chronic infection-
mediated inflammatory states.
II.) Phenotypic markers of Bregs
In early mouse studies, IL-10 production was shown
to be restricted mainly to a CD1dhiCD5+ (“B10”) subset
that comprised roughly 1–3 % of splenic B cells [37, 38].
Other phenotypically distinct B cell subsets identified in
humans exhibit immune regulatory properties through
both IL-10 dependent and independent mechanisms.
Iwata et al. [25] showed that IL-10-producing B cells in
humans were predominantly found within a CD24hiCD27+
subset that was capable of suppressing monocyte cytokine
production in vitro. Blair et al. [44] demonstrated that hu-
man CD19+CD24hiCD38hi peripheral blood B cells sup-
pressed CD4+ T cell IFN-γ and TNF-α production in vitro,
with suppressive activity that was dependent on IL-10,
CD80, and CD86. The latter two membrane proteins are
key ligands for CTLA-4, a co-inhibitory immune check-
point receptor expressed on activated effector T cells and
Tregs [53, 55]. CD19+CD25hi B cells have also been sug-
gested to represent a Breg population in humans with the
capability of suppressing CD4+ T cell proliferation and en-
hancing CTLA-4 and FoxP3 expression on Treg cells in
vitro, in a manner dependent on TGF-β but not IL-10
[56]. CD5+ B cells have also been implicated in the sup-
pression of anti-tumor immunity in humans through acti-
vation of Stat3 [57], a transcription factor that may be
involved in production of IL-10 [58].
Additional B cell expressed surface antigens have been
shown to confer regulatory properties. Programmed
Death 1 Ligand (PD-L1) interacts with PD-1 on T cells
to induce tolerance and limit effector T cell responses
[59], and has recently shown to be expressed on human
malignant B cells in several types of lymphoma including
diffuse large B cell lymphoma (DLBCL), Hodgkin’s
lymphoma, and follicular lymphoma [26–28]. Fas-Ligand
(FasL), a member of the tumor necrosis factor pathway,
interacts with its receptor FasR (CD95) to initiate a sig-
naling cascade leading to apoptosis. B cell expressed
Fas-L has been implicated in the induction of TH cell
apoptosis in HIV and EBV infections [60], and Fas-L ex-
pression on malignant B cells in lymphoid cancers such
as chronic lymphocytic leukemia (CLL) may play a role
in inhibiting anti-tumor responses by inducing TH cell
apoptosis [61]. Lindner et al. demonstrated that human
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Granzyme B-producing (GrB+) B cells are induced by
IL-21-secreting T cells, which in turn function to sup-
press T cell proliferation via GrB-dependent degradation
of the T cell receptor (TCR)- ζ-chain in vitro. GrB+ Bregs
and adjacent IL-21-producing T cells were found in the
microenvironment of several human tumors including
breast, ovarian, cervical, colorectal, and prostate tumors
[62]. These findings suggest that IL-21-dependent GrB+
Bregs may attenuate local anti-tumor immune responses
in a manner similar to Tregs, by directly inhibiting the
proliferation of CD4+ and CD8+ effector T cells.
B regulatory cells suppress cellular immune responses
and promote tumor growth in vivo through diverse
mechanisms
I) Bregs promote tumor growth and metastasis through
generation of Treg cells and suppression of effector
T cell and NK cell responses
Several murine tumors including the MC38 colorectal
cancer, EL4 thymoma, and EMT-6 mammary carcinoma
models demonstrate reduced or absent growth in B-cell
deficient mice (BCDM) compared to WT mice [4, 6, 63].
The anti-tumor effect conferred by B cell deficiency in
all three models was associated with increased T cell and
NK cell infiltration and more vigorous Th1 cytokine and
cytolytic T cell responses, and in EMT-6 was also associ-
ated with decreased proliferation of CD4+FoxP3+ Tregs.
Adoptive transfer of B cells from WT mice into tumor-
bearing BCDM restored tumor growth and Treg prolif-
eration and diminished CD8+IFN-γ+ and NK cell infil-
tration into the tumor bed. Interestingly, in contrast to
several autoimmune models the adoptive transfer of
either WT or IL-10−/− B cells was capable of rescuing
tumor growth in the EMT-6 model [63]. In the MC38
model, adoptive transfer of OX40L−/− B cells was less effi-
cient in rescuing tumor growth than WT B cell transfer,
demonstrating a role for cognate interactions between
OX40L and OX40 on B cells and T cells respectively in
modulating the anti-tumor response [64].
Pulmonary metastasis of murine 4 T1 breast cancer
requires inactivation of antitumor NK cells and expan-
sion of Treg cells [5, 65]. Olkhanud et al. [5] identified a
CD25+CD19+B220+ B cell subset designated as tumor-
evoked Bregs (tBregs), that constitutively expressed Stat3
and was expanded in 4 T1 tumor-bearing mice. In vitro,
mouse B cells treated with cancer cell-derived cultured
media (CM) but not control CM was able to suppress T
cell proliferation. Furthermore, T cell inhibitory activity
was restricted to CD25+, but not CD25− cancer-CM
treated B cells. Interestingly, peripheral blood CD19+ B
cells from healthy human donors treated with ovarian-
and colon-cancer cell-derived CM upregulated CD25
and suppressed T cell proliferation in vitro as well, sug-
gesting that human tumors may also induce a suppres-
sive CD25+ Breg population.
Non-regulatory mouse CD4+CD25−FoxP3− T cells de-
veloped increased expression of FoxP3 (thus demon-
strating conversion to Tregs) when co-cultured with
tBregs, but not control B cells, in a process that was
dependent on TGF-β. WT mice also developed expan-
sion of FoxP3+ Tregs in peripheral blood in vivo when
injected with tBregs, but not control B cells. In T- and
B-cell deficient NOD/SCID mice in which 4 T1 tumors
grow at the primary site but do not metastasize, lung
metastasis was restored with adoptive transfer of ex vivo
converted Tregs (but not non-Tregs) or with the transfer
of tBregs together with non-Tregs (but not tBregs alone),
thereby demonstrating that lung metastasis of 4 T1 tu-
mors was dependent on tBreg-mediated conversion of
non-Tregs to Tregs in vivo. These results indicate that a
unique CD25+CD19+B220+ B cell subset that constitu-
tively expresses Stat3 may be expanded by tumors, and
may in turn promote tumor metastasis through TGFβ-
dependent conversion of non-Tregs to Tregs [5, 66].
II) Bregs impair antigen-specific anti-tumor vaccines
through suppression of T and NK cell responses
Consistent with B regulatory cells having an immune-
suppressive function, antigen-specific anti-tumor vaccines
have been demonstrated to be more effective in the ab-
sence of B cells in several mouse tumor models. In the
B16 melanoma mouse model, vaccination against either of
the tumor-associated antigens (TAA) gp100 or TRP-2
using adenovirus-based vectors suppressed tumor growth
in B-cell deficient, but not WT mice. The enhanced anti-
tumor response against B16-associated tumor antigens in
BCDM was dependent on the presence of NK cells [67].
In EL-4 thymoma implanted mice, Oizumi et al. [68] dem-
onstrated using a highly immunogenic secreted form of
gp96 heat shock protein as a vaccine, that effective tumor
antigen-specific gp96-chaperone vaccination was achieved
with a single vaccination in BCDM, while repeated vacci-
nations were required to achieve a similar level of immun-
ity in WT mice. Increased CD8+ cytotoxic responses
directed against EL-4-associated tumor antigens were ob-
served in vaccinated BCDM compared to vaccinated WT
mice. These results indicated that inhibition of effects me-
diated by immune-suppressive Breg cells may help
maximize anti-tumor responses induced by vaccination.
III) Tumor-infiltrating B cells acquire LAP/TGFβ and
PD-L1 expression and suppress T and NK cell responses
EMT-6 mammary tumors are rejected or show mark-
edly diminished growth in BCDM but growth is restored
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in BCDM reconstituted with B cells [63]. Using the
EMT-6 model Zhang et al. [69] demonstrated that
tumor-infiltrating B cells (TIL-B) develop increased ex-
pression of LAP/TGF-β, CD80, CD86, and PD-L1 in
vivo compared to splenic B cells. Development of a simi-
lar B cell immunosuppressive phenotype also occurred
when B cells were co-cultured in vitro with EMT-6 cells,
and was dependent on direct physical B cell: tumor cell
contact. Functionally, these TIL-B cells demonstrated
greater ability to suppress CD4+ and CD8+ T cell prolif-
eration in response to anti-CD3/anti-CD28 co-
stimulation, and also markedly suppressed NK cell pro-
liferation in response to IL-15 compared to splenic B
cells. Monoclonal antibodies directed against TGF-β or
PD-L1 dramatically suppressed EMT-6 tumor growth in
WT mice, suggesting a potential therapeutic strategy for
targeting this specific B cell subpopulation. In addition,
TIL-B but not splenic B cells were capable of secreting
IL-10 following stimulation, suggesting that an IL-10 se-
creting subpopulation was predominantly contained
within the TIL-B population. These results point to the
local acquisition of immunosuppressive properties by B
cells migrating into the tumor bed through intimate
contact with the tumor cells. Mechanism(s) underlying
this functional transition and migration, as well as evi-
dence for similar activity in human tumors are being ac-
tively investigated.
IV)T2-MZP B cells accumulate in tumor-draining
lymph nodes and promote metastasis independently
of IL-10
B16-F10 melanoma grows significantly more slowly,
but is not completely rejected in BCDM relative to WT
mice [4]. Marked B cell accumulation in tumor-draining
lymph nodes (TDLN) of mice implanted with B16-F10
melanoma tumors precedes the development of metasta-
ses. Ganti et al. [70] showed that T2-MZP (B220+CD23
+IgMhiCD21hi) B cells preferentially accumulated in the
TDLN of tumor-bearing mice. Both tumor-implanted
BCDM and WT mice demonstrated accelerated tumor
growth when reconstituted with T2-MZP B cells, but
not other B cell subtypes. Frequencies of IL-10-secreting
B cells and FoxP3+ Tregs were not affected by T2-MZP
B cell transfer. In this model, B16-F10 melanoma in-
duces accumulation of T2-MZP Bregs in TDLN, which
in turn promote tumor growth and metastasis, and ap-
pear to do so independently of IL-10 and/or Tregs.
Further investigations are warranted to determine the
mechanism of Breg activity in this unique B cell subset.
V)Bregs promote tumor growth and metastasis
through “education” of myeloid-derived suppressor
cells
MDSCs are key regulators of tumor growth and me-
tastasis in the tumor microenvironment [71]. Using the
B16 melanoma model in which tumor growth is inhib-
ited in BCDM but restored with adoptive B cell transfer,
Bodogai et al. [72] showed that adoptive transfer of
MDSCs from B16-implanted WT mice into tumor-
bearing BCDM restored tumor growth to the same
degree as did adoptive transfer of B cells from B16-
implanted WT mice. Conversely, adoptive transfer of
MDSCs from B16-implanted BCDM into tumor-bearing
BCDM did not restore metastasis.
In human cell lines, myeloid cells sort-purified from
healthy donor PBMCs depleted of T and NK cells and
treated with CM from MDA-MB-231 breast cancer cells
were able to suppress T-cell proliferation in vitro. How-
ever, myeloid cells from donor PBMCs depleted of T,
NK, and B cells and treated with cancer-derived CM
failed to suppress T cell proliferation.
These results indicate that the immune-suppressive
and tumor-promoting functions of MDSCs may be ac-
quired through “education” by Bregs. The nature of B
cell mediated education of MDSC is unclear, but clearly
indicates a role for Breg in modulating myeloid suppres-
sor cell activity, in addition to aforementioned effects on
T and NK cells, thereby shaping the overall immune
microenvironment.
VI) The role of Stat3 activated Bregs in promoting
tumor growth and metastasis via generation of Treg
cells and promotion of angiogenesis
Consistent with the finding that CD19+CD25+ tumor-
evoked Bregs (tBregs) constitutively express Stat3 and pro-
mote tumor growth and metastasis by TGFβ-dependent
conversion of non-Tregs to Tregs [5], Lee-Chang et al.
[73] demonstrated that treatment with non-cytotoxic
doses of resveratrol (RSV), a potent inhibitor of Stat3
phosphorylation, suppressed proliferation of tBregs and
FoxP3+ Tregs in vitro, and inhibited growth of B16 and
4 T1 murine tumors in vivo. In in vitro experiments using
naïve B cells treated with 4 T1 cell-derived CM, low-dose
RSV blocked tBreg generation, Treg generation, and
reversed tBreg/Treg-mediated suppression of T cell prolif-
eration. tBregs treated with RSV also had decreased
expression of phosphorylated Stat3 (pStat3) and TGFβ
compared to mock-treated tBregs. Furthermore, RSV-
treated tBregs adoptively transferred into 4 T1 tumor-
bearing mice lacked the ability to expand FoxP3+ Tregs in
vivo and promote lung metastasis as compared to mock-
treated tBregs. These findings suggest that inhibition of
Stat3 phosphorylation in Bregs, by RSV or other methods,
may inhibit tumor growth by preventing the downstream
local elaboration of TGF-β and subsequent promotion of
FoxP3+ Tregs.
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JSI-124 (cucurbitacin I), a potent Stat3 inhibitor, also
inhibited growth of 4 T1 murine tumors. 4 T1-im-
planted mice treated with JSI-124 suppressed tumor
growth compared to non-treated mice, and B cells iso-
lated from treated mice had decreased expression of
Stat3. Consistent with the hypothesis that inhibition of B
cell-expressed Stat3 was responsible for the anti-tumor
effect of JSI-124, Stat3low B cells from treated mice ex-
hibited a tumor-suppressive effect when injected into
4 T1-bearing mice, while injection of Stat3high B cells
from non-treated mice promoted tumor growth [74].
Yang et al. [75] showed that increased tumor growth
mediated by Stat3 expression in B cells was associated with
increased tumor angiogenesis. In T- and B-cell deficient
Rag1−/− mice, growth of B16 and Lewis Lung cancer (LLC)
tumors was augmented following the adoptive transfer of
Stat3+/+ B cells, while growth was diminished with adop-
tive transfer of Stat3−/− B cells. Augmented tumor growth
with Stat3+/+ B cell adoptive transfer was associated with
increased tumor angiogenesis in vivo by Matrigel assay
and in vitro in B cell: endothelial cell co-culture assays,
and increased expression of pro-angiogenic genes by RNA
in vivo. TIL-B cells with persistently-activated Stat3 has
also been identified in several human tumors including
melanoma, gastric, lung, liver, and prostate cancers [75].
Furthermore, Stat3 activity in human tumor tissues was as-
sociated with increased density of TIL-B cells and signifi-
cantly increased intratumoral angiogenesis.
Zhang et al. [57] recently showed that CD5 positivity
among CD19 cells strongly correlated with levels of
Stat3 expression in human lung and prostate tumor tis-
sues and in corresponding TDLN, indicating that Stat3-
expressing Bregs may be contained within a CD5+ B cell
population in human tumors.
Collectively these studies indicate an important role
for Stat3 in conferring an immunosuppressive phenotype
to Breg cells, mediated in part through local elaboration
of TGF-β and through the induction of pro-angiogenic
gene expression. Inhibition of Stat3 signaling may there-
fore be a useful means of reducing or reversing Breg
promotion of tumor growth.
VII)CD19±CD1dhighCD5± Bregs infiltrate pancreatic
neoplasms and mediate tumor growth via IL-35
signaling
Pylayeva-Gupta et al. [76] recently showed that prom-
inent B cell infiltrates are frequently present in human
pancreatic intraepithelial neoplasia (PanIN) and in pan-
creata of mice harboring Kras-driven pancreatic neo-
plasms. In addition, implantation of pancreatic ductal
epithelial cells expressing oncogenic Kras (KrasG12D)
into WT mice pancreata leads to infiltration of B cells
adjacent to the newly developing tumor. KrasG12D
pancreatic tumor growth is diminished in BCDM but
tumor growth is restored following B cell adoptive trans-
fer, which is accompanied by de novo tumor infiltration
with the adoptively transferred B cells.
Since the CD1dhiCD5+ B cell population has been
shown to mediate immune-suppression via IL-10 secre-
tion [37, 38] and IL-35 [77] in mouse autoimmune and
tumor models, Pylayeva-Gupta et al. investigators hypoth-
esized that CD1dhiCD5+ B cells would also regulate
immune-suppression and promote tumor growth in the
mouse pancreatic ductal adenocarcinoma (PDAC) model.
Adoptive transfer of CD19+CD1dhiCD5+ B cells but not
CD19+CD1dloCD5− B cells rescued tumor growth in
BCDM inoculated with KrasG12D. Adoptive transfer of IL-
10−/− B cells was capable of rescuing tumor growth in
BCDM inoculated with KrasG12D to the same extent as
WT B cells, however tumor growth remained suppressed
with adoptive transfer of IL-12α−/− B cells, indicating that
promotion of tumor growth by infiltrating CD1dhiCD5+ B
cells in this PDAC model is mediated by IL-35, a heterodi-
mer comprised of p35 and EBI3 subunits encoded by the
genes IL12α and EBI3, respectively.
IL-35+ Bregs have been shown to inhibit Th1 and Th17
cells and promote Treg expansion in a mouse model of
autoimmune uveitis [77]. IL-35 has also been shown to
promote growth of human pancreatic cancer cells in
vitro [78], and has been shown to be upregulated in the
sera of patients with pancreatic cancer [79]. Together,
these results suggest that B cells may infiltrate pancre-
atic neoplasms and promote tumor growth via suppres-
sion of antitumor immunity through IL-35 secretion. IL-
35 mediated Breg suppression of tumor immunity may
also be a suitable target for therapeutic intervention in se-
lect human tumors.
VIII)Bruton’s tyrosine kinase (BTK) expression in B
cells and macrophages, as a target for regulation of
immune-suppressive phenotypes
Previous findings by Affara et al. [80] and Andreu et al.
[81] suggested that TIL-B cells promote tumor growth in
squamous cell carcinoma (SCC) models through inter-
actions with Ig receptor FcRγ +myeloid cells and subse-
quent repolarization of TAM towards an immune-
suppressive type (“M2”-type). Gunderson et al. [82]
showed that mouse PDAC tumors were heavily infil-
trated with B cells and FcRγ +myeloid cells, and fur-
thermore that tumor growth was diminished in BCDM
and Ig-receptor null FcRγ−/− mice. Based on these ob-
servations, investigators hypothesized that signaling
pathways common to both B cells and macrophages,
such as BTK signaling, may be involved in the suppres-
sion of antitumor immunity by infiltrating lymphocytes
in PDAC tumors. In accordance with this hypothesis,
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activated BTK (pBTK) was identified in murine PDAC
tumors in single-cell suspensions and was most prom-
inent in CD19+ B cells and CD11b+ myeloid cells.
In in vitro assays using PDAC-derived B cells co-
cultured with macrophages, PDAC-derived B cells en-
hanced macrophage expression of Th2 cytokines. In
contrast, the pre-treatment of PDAC-derived B cells
with the BTK inhibitor ibrutinib instead enhanced
macrophage expression of Th1 cytokines. These results
indicate that inhibition of BTK in tumor-infiltrating B
cells may promote macrophage repolarization from an
immune-suppressive, tumorigenic M2-type toward a
pro-inflammatory, anti-tumor M1-type.
In vivo, early stage PDAC tumor-bearing mice treated
with ibrutinib exhibited significantly diminished tumor
growth. Treatment of late-stage tumor-bearing mice
treated with ibrutinib plus gemcitabine resulted in sig-
nificantly diminished tumor growth compared to gemci-
tabine alone. BTK may therefore represent a novel
potential target for reduction of Breg cell activity in can-
cer, and furthermore BTK inhibition may augment the
efficacy of chemotherapy.
Ibrutinib has recently been approved by the FDA for
treatment of patients with refractory or p53-mutated CLL
[83], as well as patients with relapsed mantle cell lymph-
oma [84]. These findings have provided a rationale for
clinical trials examining the use of ibrutinib as adjunctive
therapy to gemcitabine and nab-paclitaxel in metastatic
pancreatic carcinoma (NCT02562898, NCT02436668).
IX)A link between 4-1BBL expression on B cells and
the generation of cytotoxic Granzyme-B+ T cells
Interestingly, depletion of B cells with an anti-CD20
antibody (α-CD20 mAb) in WT mice prior to inocula-
tion with 4 T1 cells blocked metastasis of 4 T1 tumor,
consistent with findings observed in genetically B-cell
deficient mice [85]. However, administration of α-CD20
mAb to WT mice with established 4 T1 tumors unex-
pectedly resulted in significantly enhanced tumor growth
and metastasis.
Bodogai et al. [85] reconciled this paradoxical result by
demonstrating that α-CD20 mAb treatment of 4 T1
tumor-bearing mice enriches for B cells that are pheno-
typically CD20low and have enhanced T cell-suppressive
effects ex vivo compared to B cells from control IgG2a-
treated tumor-bearing mice. Consistent with these find-
ings in mice, co-culture of human peripheral blood B
cells with human breast cancer or colon cancer cells re-
sulted in emergence of a CD20low Breg population that
suppressed T-cell activity and was sustained after treat-
ment with α-CD20 mAb in vitro.
Screening for TLR ligands capable of inactivating
Bregs revealed that the TLR9 ligand CpG-ODN was able
to upregulate CD20 and block the T cell-suppressive ef-
fects of human and murine tBregs in vitro. Treatment of
4 T1 tumor-bearing mice with CpG-ODN abrogated
lung metastasis, and ex vivo B cells derived from CpG-
ODN treated tumor-bearing mice induced T cell prolif-
eration and expansion of GrB+CD8+ cytolytic T cells.
Enhancement of metastasis by α-CD20 mAb treatment
was completely reversed in vivo when α-CD20 mAb-
treated tumor-bearing mice were adoptively transferred
with CpG-ODN-pretreated B cells from syngeneic naïve
mice. In contrast, adoptive transfer of mock-treated B
cells minimally reduced the enhanced lung metastasis
following α-CD20 mAb treatment.
4-1BBL (CD137L) is an immune co-stimulatory recep-
tor and a member of the TNF receptor family, which
activates CD8+ T cells and NK cells via cross-linking of
4-1BB (CD137) expressed primarily on T cells [86]. Bod-
ogai et al. [85] investigators observed that human and
murine CD20low Bregs also had reduced 4-1BBL expres-
sion compared to normal B cells. Treatment with CpG-
ODN reversed the reduced expression of 4-1BBL on
murine and human Bregs in vitro as well as in vivo in
tumor-bearing mice, resulting in emergence of a CD20high4-
1BBLhigh B cell subset.
Consistent with the results seen in the 4 T1 murine
model, the depletion of B cells using α-CD20 mAb in
mice inoculated with EMT-6 did not result in tumor re-
jection as expected, and was associated with a paradox-
ical increase of CD4+FoxP3+ Tregs in the spleens of
treated mice, although a role for 4-1BBL was not investi-
gated in the EMT-6 model [63].
These results suggest that tumors can induce a popu-
lation of CD20low4-1BBLlow immune-suppressive Bregs
that are relatively enriched following α-CD20 mAb treat-
ment. Relative enrichment of CD20low4-1BBLlow Bregs
therefore is a plausible explanation for the failure of ri-
tuximab to provide a clinical benefit when combined
with IL-2 immunotherapy for patients with renal cell
carcinoma and melanoma [87]. Treatment strategies di-
rected toward facilitating the conversion of 4-1BBLlow
Bregs to immune-stimulatory 4-1BBLhigh B cells, as
demonstrated using CpG-ODN in the 4 T1 model [85],
may therefore be a useful strategy to reverse tumor-
mediated induction of suppressive Bregs.
X) IgA+CD138+PD-L1+IL-10+ Bregs impede expansion
of anti-tumor cytotoxic T-lymphocytes (CTL)
induced by oxaliplatin chemotherapy
In both the TRAMP and Myc-Cap (MC) mouse
models of metastatic prostate carcinoma (PC), large tu-
mors (>0.7 g, >350–400 mm3 respectively) were resistant
to treatment with low-dose oxaliplatin in WT mice but
were sensitive to treatment in BCDM [88]. The anti-
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tumor effect conferred by B cell deficiency was associ-
ated with enhanced CD8+ cell infiltration in both tumor
types. Treatment of tumor-bearing WT mice with oxali-
platin was associated with emergence of a tumor-
infiltrating CD19+CD138+IgA+ plasma cell population
that expressed IL-10, PD-L1, phosphorylated Stat3, and
Fas-L. Reconstitution of tumor-bearing BCDM with WT
B cells, but not PD-L1−/− or IL-10−/− B cells, could restore
tumor growth in oxaliplatin-treated mice, implicating both
PD-L1 and IL-10 in mediating the Breg suppressive ef-
fects. In addition, ablation of B cell TGFβR2 inhibited
oxaliplatin-induced IgA+ plasma cell generation, blocked
induction of tumoral PD-L1+ by oxaliplatin and was asso-
ciated with increased tumoral CTL density and IFN-γ
production, thus implicating TGF-β signaling in the gen-
eration of this Breg subpopulation. Large MC tumors re-
sistant to treatment with oxaliplatin monotherapy showed
diminished tumor growth when treated with oxaliplatin
plus anti-PD-L1, but not with anti-PD-L1 alone.
In human prostatectomy samples, CD8+ and CD20+
cell density was higher in patients with PC compared to
healthy controls, and correlated significantly with ad-
vanced stage and treatment failure [88]. IL-10-producing
IgA+CD138+ plasma cells were also present in human PC
samples but were more abundant in metastatic PC and
therapy-resistant PC compared to early stage disease.
These results indicate that treatment with an immuno-
genic chemotherapeutic agent, oxaliplatin, may induce a
CD138+IgA+PD-L1+IL-10+ Breg population generated
via a TGFβ-dependent pathway that limits the effective-
ness of oxaliplatin by inhibiting intratumoral CTL
infiltration. This further suggests that the successful
treatment of large prostate tumors with oxaliplatin may
require the elimination of these immunosuppressive IgA
+ plasma cells that are present in both mouse and hu-
man PC, and suggests a rational approach to augment-
ing beneficial chemotherapy effects on the anti-tumor
immune response. Targeting of the PD-L1/PD-1 axis
may be an especially useful strategy in this regard.
A summary of reported B reg phenotypic markers and
functional attributes is presented in Table 1, and several
of the key reported interactions reviewed above are sche-
matically represented in Fig. 1.
B cell effects on carcinogenesis
I) B cells are involved in de novo carcinogenesis in
murine models of inflammation-associated squamous
cell carcinoma
Several landmark studies also point to a role for B cells
in facilitating carcinogenesis, mediated through effects on
local inflammation [80, 81, 89, 90]. In the K14-HPV16
(HPV16) transgenic mouse model of inflammation-
associated de novo epithelial carcinogenesis, the absence
of T- and B-lymphocytes (generated by intercrossing with
Rag1−/− mice) limits immune cell infiltration and attenu-
ates characteristic markers of premalignancy such as
VEGF-A activity, matrix metalloproteinase activity, epithe-
lial hyperproliferation, and development of angiogenic
vasculature [89]. Subsequently, neoplastic progression is
abrograted in HPV16/Rag1−/− mice. Premalignant HPV16
skin was characterized by enhanced immunoglobulin (Ig)
deposition, suggesting that B cells initiate Ig deposition
into neoplastic tissue, paralleling inflammation and pre-
malignant progression in HPV16 mice. Accordingly, skin
from HPV16/Rag1−/− mice had diminished Ig deposition
and reduced immune cell infiltration. Adoptive transfer of
B cells or serum, but not T cells from HPV16 mice into
HPV16/Rag1−/− mice restored Ig deposition, innate im-
mune cell infiltration and premalignant characteristics
and facilitated progression to epithelial carcinogenesis.
Based on these findings, Affara et al. [80] showed that
B cell depletion with α-CD20 mAb restricted premalig-
nant progression in K14-HPV16 transgenic mice. In
contrast, α-CD20 mAb treatment did not affect growth
of SCC tumors derived from K14-HPV16 mice that were
orthotopically implanted into syngeneic WT mice. How-
ever, α-CD20 mAb treatment in combination with the
chemotherapy (CTX) agents cisplatin, carboplatin, or
paclitaxel, each ineffective on their own, resulted in
tumor regression in mice orthotopically implanted with
SCC tumors. Further analysis revealed that combinator-
ial α-CD20 mAb/CTX treatment was associated with
increased tumor CD8+ infiltration compared to CTX
treatment alone. Similar to aforementioned findings in a
mouse model of prostate cancer [88], these results indi-
cate the efficacy of augmenting chemotherapy with B-
cell depletion strategies to improve outcomes.
Based on the findings implicating B cells in squamous
carcinogenesis in mice [80, 89], and other previous stud-
ies showing that TNF-α deficient mice are resistant to
chemical carcinogenesis of the skin [91], Schioppa et al.
[90] investigators hypothesized that TNF-α might be in-
volved in the tumor-promoting actions of B cells.
In a 7,12-dimethylbenz[α]anthracene/terephthalic acid
(DMBA/TPA) mouse model of chemical-induced skin
carcinogenesis, DMBA/TPA-induced papilloma develop-
ment was blocked in B- and T-cell deficient Rag2−/−
mice. Reconstitution of DMBA/TPA-treated Rag2−/−
mice with B cells from DMBA/TPA-treated WT mice
restored papilloma growth, whereas reconstitution with
B cells from DMBA/TPA-treated TNFα−/− mice failed to
restore papilloma growth, thereby implicating TNFα-
producing B cells as key mediators of tumorigenesis in
this model. TNFα−/− mice treated with DMBA/TPA also
had reduced absolute numbers of splenic IL-10+CD19+
cells and increased absolute numbers of CD8+IFN-γ+ T
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Table 1 Breg markers of immune suppression and tumorigenesis
Breg marker Mechanisms Phenotype(s) Cancer type(s) References
IL-10 ↓Th1/Th17; ↑Treg generation Human: HNSCC, lung, esophageal, ovarian,
glioma, gastric
[5, 13–22, 25, 37,







CD19 + CD25 + B220+
Granzyme-B ↓T cell proliferation via degradation of
TCR-zeta chain
Human: Breast, ovarian, cervical, colorectal,
prostate
[62]
CD19 + CD38 + CD1d +
IgM + CD147+














Lymphotoxin-α/β Activation of IKKα and STAT3 Mouse: Castration-resistant prostate (mice) [93]
CD19 + LT+
PD-L1 Promote T cell anergy via interaction
with PD1





PD-1 Promote T cell anergy Human: Hepatocellular [15]
CD19 + CD5hiCD24−/+
CD27hi/+CD38dim
TNFα ↑IL-10+ Bregs, ↓CD8 + IFNγ Tcells Mouse: Squamous cell skin CA (mice) [90]
CD19 + TNFα+
OX40L ↑Th2 skewing, ↓CD8 + IFNγ Tcells Mouse: Colorectal (mice) [64]
CD19 + OX40L+
CD80, CD86 ↓T cell proliferation via interaction with
CTLA-4; may also ↑T cell proliferation
via interaction with CD28
Human Multiple tumor types [30, 44, 69]
CD19+CD24hiCD38hi




FasL Induce T cell apoptosis via binding to Fas Human: CLL [60, 61]
Malignant B cells
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cells in the spleen and lymph nodes compared to DMBA/
TPA-treated WT mice. Together, these results suggest
that TNFα secretion by B cells may regulate tumor growth
through production of IL-10+ Bregs, which in turn attenu-
ate CD8+IFN-γ+ T cell responses.
These studies suggest a unique B cell role in promot-
ing a local inflammatory response, in turn leading to
squamous carcinogenesis. Mechanisms underlying this
role warrant further investigation but may involve en-
hanced inflammatory responses [81, 89] or local elabor-
ation of TNF-α [90], both leading to enhanced myeloid
cell infiltration and reduced CD8+ T cell infiltration.
Interestingly, B cell depletion with α-CD20 mAb was ef-
ficacious in suppressing tumor growth as an adjunct to
chemotherapy in the squamous carcinoma mouse model
[80] and was efficacious as monotherapy in a mouse
model of pancreatic cancer [92], however treatment with
α-CD20 mAb accelerated tumor growth in mouse breast
cancer models [64, 85]. Further investigations are war-
ranted to determine how Breg induction may differ
among tumor types and identify tumors that may be re-
sponsive to α-CD20 mAb treatment.
Table 1 Breg markers of immune suppression and tumorigenesis (Continued)
CD40L Interact with CD40 on malignant cells
to stimulate ↑IL-10, ↑TGFβ
Human: Hepatocellular [19]
CD19+CD24hiCD38hi
CD5 Activation of Stat3 via binding to IL-6 Human: Lung, prostate [57]
CD19+CD5+IL-10+
BTK Repolarization of macrophages toward
M2-type
Mouse: Pancreatic (mice) [82]
CD19 + BTK+
Fig. 1 Tumor educated B regulatory cells suppress anti-tumor immunity. Tumor cell secreted chemokines such as CXCL13, may attract naïve B
cells into the tumor microenvironment. Tumor cells and tumor infiltrating Treg cells may express inhibitory molecules (e.g. PD-L1) and/or secrete
cytokines (e.g. IL-21, IL-35, or TGF-β) that may promote differentiation of B cells leading to development of a B regulatory phenotype (Breg cells).
Breg cells may undergo activation of Stat3, and also upregulate key regulatory or inhibitory molecules such as PD-L1, CD25, CD86, LAP/TGF-β,
and Granzyme B, and secrete cytokines, such as IL-10, IL-35 and TGF-β. Breg cells can suppress T and NK cell activation, proliferation and function
in vivo and also ‘educate’ MDSC and tumor associated macrophages (TAM) to suppress anti-tumor immunity. Breg cells have also been noted to
support natural Treg cell expansion and the conversion of effector CD4+ T cells into inducible Treg cells. Breg cells may also facilitate macrophage
differentiation into TAM-M2 macrophages and increase local inflammation and thereby promote carcinogenesis in certain settings. Further details
and supporting references in text
Schwartz et al. Journal for ImmunoTherapy of Cancer  (2016) 4:40 Page 9 of 15
II) B cell infiltration of androgen-ablated prostate
tumors in mice drives the development of castrate-
resistant prostate cancer
In a mouse model of prostate cancer (myc-CaP),
Ammirante et al. [93] demonstrated that castration of
myc-CaP tumor-bearing mice results in the accumula-
tion of an immune infiltrate comprised of B and T
lymphocytes, NK cells, and myeloid cells in dying
androgen-deprived primary tumors. This process pre-
cedes the emergence of castration-resistant prostate
(CR-CaP) tumors. To further explore the role of tumor-
infiltrating lymphocytes (TILs) in the emergence of CR-
CaP, irradiated WT mice were reconstituted with bone
marrow (BM) derived from either WT or Rag1−/− mice
and then inoculated with myc-CaP tumors, followed by
castration 8 weeks later. Both groups showed identical
growth of the primary tumor, however CR-CaP tumor
growth after castration was significantly delayed in mice
reconstituted with Rag1−/− BM compared to WT BM.
More rapid emergence of CR-CaP was restored when ir-
radiated mice were reconstituted with TCRβ−/− BM,
however CR-CaP growth remained delayed when irradi-
ated mice were reconstituted with JH
−/− BM, indicating
that elimination of B cells rather than T cells was re-
sponsible for delayed growth of CR-CaP. Further mech-
anistic analysis revealed that secretion of lymphotoxin
(LT) by infiltrating B cells stimulates LTβR on CaP cells
to induce nuclear translocation of IKKα and activation
of STAT3, thereby driving androgen-independent tumor
growth after castration. Inhibition of IKKα, STAT3,
LTβR, as well as B cell-specific LTβ ablation were each
independently capable of delaying CR-CaP growth. This
study invokes a completely novel mechanism by which
local elaboration of a cytokine by infiltrating B cells may
indirectly stimulate tumor growth. The relationship be-
tween androgen deprivation and B cell mobilization is
poorly understood. Whether similar pathogenesis will be
seen in human castration-resistant prostate cancer is not
known.
III) B cell recruitment is regulated by HIF1α stabilization
and promotes tumor growth in a murine model of
pancreatic ductal adenocarcinoma
Hypoxia, a central feature of the tumor microenviron-
ment, drives the expression of hypoxia-inducible factors
on tumor cells including HIF1α, which regulates expres-
sion of genes involved in metabolism, angiogenesis, cell
survival, and inflammation [94, 95]. Lee et al. [92]
showed that hypoxia-driven HIF1α expression and
stabilization occurred in the early growth stages of both
murine KrasG12D PDAC and human PDAC tumors, and
that the deletion of pancreas-specific Hif1α in mice
harboring KrasG12D tumors resulted in accelerated tumor
growth and was associated with an influx of intra-
pancreatic B cells. Human PDAC tumors also showed sig-
nificant intra-pancreatic B cell infiltration. B-cell depletion
in KrasG12D/HIF1α-KO mice following treatment with α-
CD20 mAb significantly decreased the number of grade 3
PanIN lesions and reduced the percentage of mice with
microinvasive lesions, indicating that the accelerated
tumor growth in HIF1α-KO mice is due at least in part re-
lated to increased intrapancreatic B-cell recruitment.
Increased secretion of the B-cell chemokine CXCL13
in HIF1α-KO mice was believed to be responsible for
the prominent influx of intrapancreatic B cells, as
CXCL13 levels by ELISA and immunohistochemical
staining were significantly higher in KrasG12D/HIF1α-KO
mice compared to KrasG12D and WT mice. CXCL13 pro-
tein accumulation was also detected in the majority of hu-
man PDAC tumor samples.
Together, these observations indicate that hypoxia may
accelerate the growth of HIF1α-deleted PDAC tumors in
part by augmenting intrapancreatic B-cell accumulation,
which appears to be driven by local expression of the B
cell chemokine CXCL13. Therefore HIF1α expression
and stabilization may actually inhibit tumor B cell infiltra-
tion and thus may be a protective mechanism in response
to tissue hypoxia. The effects of HIF1α signaling on local
B cell recruitment represent a unique and unanticipated
effect of hypoxia on the composition of tumor immune
infiltrates and subsequent anti-tumor response.
IV) IV. B cells are actively recruited to bladder tumors
and promote tumorigenesis via secretion of IL-8
Ou et al. [22] demonstrated that human bladder can-
cer (BCa) tissues are capable of recruiting more B cells
than surrounding normal bladder tissues. In turn, B cell
infiltration in BCa tissues increases BCa cell invasiveness
as demonstrated in in vitro chamber invasion assays
using three separate human BCa cell lines cocultured
with B cells. In addition, mice xenografted with human
J82 BCa cells and co-implanted with B cells developed
significantly more metastatic foci in vivo compared to
mice implanted with J82 cells alone.
Increased expression of androgen receptor (AR) by
tumor cells was associated with increased BCa invasive-
ness. AR signaling has been implicated in bladder carcino-
genesis, as androgen deprivation has been shown to inhibit
tumor growth in mouse models and xenografts [96].
Further investigation revealed that B cells augment AR
expression in human BCa tissue by secreting IL-8, a pro-
inflammatory chemokine shown to promote bladder car-
cinogenesis and metastasis [97, 98]. In turn, increased AR
expression leads to upregulation of the matrix metallopro-
teinases MMP1 and MMP13, mediators of extracellular
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collagen degradation with known roles in tumor invasion,
metastasis, and BCa progression [98, 99]. Knockdown of
AR expression, inhibition of MMP1 and MMP13, or the
use of anti-IL-8 neutralizing antibody all reversed the abil-
ity of B cells to increase BCa cell invasion.
This study highlighted a role for local elaboration of
chemokines such as IL-8 by infiltrating B cells in pro-
moting tumor invasion. It appears that the effect of IL-8
may be to upregulate AR expression on BCa cells and
thereby increase expression of the AR-downstream pro-
metastatic collagenases MMP1 and MMP13. The rela-
tionship between inflammation and upregulation of AR
expression is unclear. Therapeutic strategies directed
against Breg secretion of IL-8 and/or disruption of the
IL-8/AR/MMP1/MMP13 pathway in BCa warrant fur-
ther exploration.
B regulatory cells in human solid tumor malignancies
I) CD20± B cell and plasma cell infiltration of tumors
have diverse effects on tumorigenesis
To date, most studies evaluating the prognostic signifi-
cance of TILs have focused on T cells, while less atten-
tion has been devoted toward TIL-B cells. Using high
resolution gene expression arrays, Schmidt et al. [11]
showed that expression of a B cell “metagene” signature
consisting of 60 genes in tumors from patients with
node-negative breast cancer significantly correlated with
metastasis-free survival. Tumor expression of the IgG+
plasma cell marker immunoglobulin kappa C (IGKC)
provided prognostic information that was comparable
with that of the B cell metagene signature in breast can-
cer patients. IGKC expression was also associated with
better prognosis in non-small cell lung cancer (NSCLC)
and colorectal adenocarcinoma (CRC) cohorts [11]. In
another cohort of patients with CRC, higher density of
tumor CD20+ B cell infiltration as measured by immu-
nohistochemistry (IHC) correlated significantly with im-
proved overall survival [7]. This data suggests that an
immune response may actually be mediated by B cells in
the aforementioned examples.
Increased tumor infiltration of CD20+ B cells has also
been shown to portend a better prognosis among pa-
tients with epithelial ovarian cancer (EOC). Nielsen et al.
[100] demonstrated that CD20+ B cells co-localized with
CD8+ T cells in tumor specimens from patients with
high-grade serous ovarian cancer (HGSC), raising the
possibility that TIL-Bs act as antigen-presenting cells to
facilitate the antitumor T cell cytolytic response. Consist-
ent with the hypothesis that TIL-Bs may have an anti-
tumor effect when co-localized with CD8+ T cells,
Kroeger et al. [10] showed that TIL-B- and T-cells co-
localize and arrange in tertiary lymphoid structures
(TLS) surrounded by dense IgG+ plasma cell infiltrates
in HGSC tumors. CD8+ TILs conferred a better progno-
sis only in the presence of adjacent CD4+ T cell TILs,
CD20+ B cell TILs, and CD138+ plasma cells. Plasma
cells adjacent to TLS may confer an anti-tumor effect
via antibody-related mechanisms such as complement
activation or antibody-dependent cellular cytotoxicity
(ADCC) [10].
In contrast to the above observations, other studies
have demonstrated an increase in CD20+ and CD138+
cell infiltration in association with a poorer prognosis.
Lundgren et al. [8] demonstrated that in patients with
EOC, increased tumoral CD20+ and CD138+ expression
by IHC was associated with advanced tumor grade, and
CD138 expression correlated significantly with reduced
overall and cancer-specific survival. In patients with pri-
mary operable invasive ductal breast cancer, increased
CD138+ B-cell infiltration was also independently associ-
ated with poorer recurrence-free survival [23]. In pa-
tients with prostate cancer, increased tumor CD20+
density correlated significantly with D’Amico high-risk
categorization, and was predictive of treatment failure
[24]. In addition, Prueitt et al. [12] showed that immu-
noglobin expression by TIL-B cells was increased in ac-
tive smokers with PC, who are known to have a higher
incidence of metastatic disease, compared to past or
never smokers with PC.
Studies examining the prognostic significance and ef-
fects on anti-tumor immunity of tumor-infiltrating
CD20+ B cells and CD138+ plasma cells have therefore
yielded conflicting results. CD20+ B cells may function
to present tumor antigen to cytotoxic T cells or other
immune effector cells, and plasma cells may secrete anti-
bodies that aid in the immune response against tumor
cells [7, 10, 11, 100]. Alternatively, CD20+ and CD138+
TIL-Bs may function to suppress T cell anti-tumor re-
sponses as in Bregs or promote tumor progression by
nurturing an inflammatory microenvironment. Better
characterization of the immunophenotype of Breg sub-
populations may clarify the nature of these conflicting
results.
II) Bregs are upregulated in patients with solid tumors
and are associated with more aggressive disease
In contrast to the conflicting results regarding sig-
nificance of general tumor infiltration with CD20+ B
cells and CD138+ plasma cells in humans, the major-
ity of studies examining infiltration of tumors with B
cells that have an established regulatory phenotype
(CD38hiCD24hi, CD5 + CD1dhi, CD24hiCD27+, IL-10+)
have demonstrated that Breg infiltration is associated
with impaired anti-tumor immunity and more aggres-
sive disease [13–22].
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In patients with esophageal cancer, frequencies of per-
ipheral blood IL-10+ Bregs were significantly greater com-
pared with healthy controls [17]. IL-10+ Breg frequency
also correlated with clinical staging and disease progression
in esophageal cancer patients, as higher frequencies were
seen in the peripheral blood of patients with Stage III/IV
disease compared to early stage disease patients [17].
Wei et al. [16] demonstrated that in patients with
ovarian cancer and ascites, CD19+IL-10+ Breg frequency
was increased in ascitic fluid compared to peripheral
blood. Furthermore, frequency of ascitic IL-10+ Bregs
correlated with advanced stage and was associated with
increased ascitic CD4+FoxP3+ Treg frequency and de-
creased ascitic CD8+IFN-γ+ T cell frequency. Ex vivo,
ascitic fluid B cells from ovarian cancer patients sup-
pressed IFN-γ production by CD8+ T cells.
Analysis of biopsy specimens from patients with
tongue squamous cell carcinoma (TSCC) revealed in-
creased frequency of CD19+IL-10+ Bregs in tumor tissue
and metastatic lymph nodes compared to adjacent nor-
mal tissue [13]. Increased tumor IL-10+ Breg frequency
was also associated with increased FoxP3+ Treg infiltra-
tion and reduced survival.
Wang et al. [20] showed that CD19+CD24hiCD38hi IL-
10+ Bregs were more prevalent in the peripheral blood
of patients with gastric cancer versus healthy controls.
In gastric cancer patients, IL-10+ Bregs were more
prevalent in tumor tissues versus non-tumoral tissues
and peripheral blood. Ex vivo, gastric cancer Bregs sup-
pressed IFN-γ and TNF-α secretion by CD4+ cells and
mediated conversion of CD4+ cells to CD4+FoxP3+ Tregs
via TGF-β signaling.
In patients with CRC, CD24hiCD38hi Bregs and
CD24hiCD27+ Bregs were present in tumors and the fre-
quency of CD24hiCD38hi Bregs was significantly elevated
in advanced stage tumors. Liver metastases from CRC
had lower frequencies of B cells comprising the immune
cell infiltrate compared to primary tumors, however the
proportion of B cells with a regulatory phenotype was
significantly increased in metastatic tissue, possibly indi-
cating a shift in B cells toward a more immunosuppres-
sive phenotype within the metastases [21].
Increased peripheral blood IL-10+ Bregs were observed
in patients with NSCLC compared to healthy controls,
and increased peripheral IL-10+ Bregs in NSCLC pa-
tients correlated with an increase in peripheral FoxP3+
Tregs and MDSCs [18]. Furthermore, increased periph-
eral IL-10+ Breg frequency was associated with more ag-
gressive disease progression and advanced stage. While
Zhou et al. [14] also identified increased frequency of
peripheral Bregs in lung cancer patients versus controls,
they unexpectedly also showed decreased frequency of
peripheral Tregs, but speculated that lung tissues might
show increased Tregs.
In tumor specimens from patients with hepatocellular
cancer (HCC), the prevalence of intrahepatic B cells at the
tumor margin was associated with tumor-invasive features
[19]. Peripheral blood CD19+CD24+CD38+ Breg fre-
quency was significantly greater in HCC patients versus
healthy controls, and circulating Breg frequency correlated
with advanced staging. Higher expression levels of CD40L
were observed on Bregs versus non-Bregs as well.
SCID mice injected with human MHCC-97 L HCC
cells mice together with human CD19+CD24+CD38+
Bregs demonstrated markedly larger tumor growth at
6 weeks and increased serum IL-10 levels compared to
SCID mice injected with HCC cells and CD19+CD24
−CD38− non-Bregs. In in vitro co-culture studies, Bregs
increased HCC cell proliferation, promoted secretion of
IL-10 and TGF-β1 and decreased secretion of TNF-α
compared to non-Bregs. CD40 was upregulated on HCC
cells co-cultured with Bregs as well. Administration of
anti-CD40L antibody blocked HCC tumor growth en-
hancement by Bregs in vivo, blocked enhancement of
HCC cell proliferation by Bregs in vitro and decreased
IL-10 and TGF-β1 secretion while promoting an in-
crease of TNFα secretion. These results suggest that an
expanded CD19+CD24+CD38+ peripheral blood Breg
population in patients with HCC may migrate to the
tumor margin and mediate tumor growth via local elabor-
ation of immunosuppressive cytokines IL-10 and TGF-β,
dependent on cognate interactions between CD40L and
CD40 on Bregs and HCC cells respectively. Targeting of
the CD40L/CD40 pathway may therefore be a possible
therapeutic strategy in patients with advanced HCC.
Recently, a novel tumor-promoting PD-1high Breg subset
with CD5highCD24−/+CD27high/+CD38dim phenotype was
identified in tumor tissues of patients with HCC and corre-
lated with advanced stage and early disease progression.
Investigators identified increased tumor infiltration with
PD-1high Bregs which produced IL-10 upon interaction
with PD-L1 or anti-PD1 antibody. Increased tumor infiltra-
tion with PD-1high IL-10-producing Bregs was associated
with reduced number and dysfunction of CD8+ cells. These
findings identify a uniquely suppressive PD-1+ B cell subset
in HCC pathogenesis. Therefore, PD-1 may also be viable
target for the reduction of Breg activity in HCC [15].
These studies suggest that frequencies of B cells with
regulatory phenotypes are increased in the peripheral
blood of patients with various solid tumor types compared
to age-matched controls. Also, there is evidence that B
cells with regulatory phenotypes accumulate in the tumor
tissues and peri-tumoral environment. It is not clear if
Bregs are actively promoting tumor growth in humans or
if an increase in Bregs is merely an immune response
against the tumor, however aforementioned ex vivo and
xenograft assays demonstrating suppressive properties of
Bregs gives credence to the former hypothesis.
Schwartz et al. Journal for ImmunoTherapy of Cancer  (2016) 4:40 Page 12 of 15
Conclusions
It has become clear that in both mouse models and in
humans that B cells can mediate immunosuppression
through modulation of innate and/or adaptive immune
responses in support of tumor growth. In several murine
model systems B cells are actively recruited to tumors
and directly acquire suppressive activity within the
tumor bed [69]. Signaling through diverse pathways such
as BTK, NF-kB and/or STAT3 has been implicated in
the generation of the Breg phenotype.
A variety of cytokines secreted by Bregs have been im-
plicated in the suppression of anti-tumor immunity in-
cluding IL-10, IL-35, IL-6, and TGF-β. Additionally,
Bregs may express a variety of suppressive ligands in-
cluding PD-L1, PD-1, CD80, CD86, LAP-TGF-β, Fas-L,
CD40L, and OX40L. Bregs may also express proteases such
as Granzyme-B that directly impair T cell function [62].
Bregs may support expansion of suppressive Tregs and
MDSCs, suppress stimulatory Th1/Th17 cells, promote
skewing of T-helper cells and macrophages toward sup-
pressive Th2/M2 types, and/or may interact directly with
effector CD4+ and CD8+ T cell and/or NK cells to sup-
press anti-tumor immunity.
B cells may also directly promote carcinogenesis
through local elaboration of inflammatory mediators
such as TNF-α in squamous cell skin cancer [90], lym-
photoxin in prostate cancer [93], and IL-8 in bladder
cancer [22]. Antibody production and subsequent depos-
ition of immune-complexes in tumor tissue is another
mechanism whereby B cells may promote inflammation
and neoplastic progression. B cells may also facilitate
tumorigenesis through the upregulation of pro-angiogenic
genes.
The list of human tumors infiltrated with B cells is
rapidly expanding. B cell infiltration of tumors has been
associated with improved prognosis or alternatively with
enhanced tumor aggressiveness in different studies.
Studies examining B cells with regulatory phenotypes
however suggest uniformly that Breg infiltration may en-
hance tumor progression.
B cell depletion can be accomplished using α-CD20
mAb such as rituximab and obinatuzumab, or through
use of inhibitors of signal transduction such as ibrutinib.
B cell depletion strategies deployed in combination
with current immune therapies requires further study.
Not all forms of B cell depletion may be equally effect-
ive, as demonstrated by the failure or limited effective-
ness of α-CD20 mAb therapy in several tumor models.
Further investigations are necessary to identify Breg-
specific targets that may be selectively used to deplete
key B cell subpopulations with regulatory function, and/
or to modulate B cell-T effector cell cross-talk through
co-stimulatory ligands, cytokines, and/or chemokines to
augment anti-tumor effector responses.
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